Calliditas Therapeutics AB (publ) (CALT) Scheduled to Post Earnings on Monday

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) is set to issue its quarterly earnings data before the market opens on Monday, November 11th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) last issued its earnings results on Tuesday, August 13th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.09. The business had revenue of $52.36 million for the quarter, compared to analysts’ expectations of $42.89 million. Calliditas Therapeutics AB (publ) had a negative return on equity of 212.04% and a negative net margin of 30.18%. During the same period in the previous year, the firm posted ($0.33) EPS. On average, analysts expect Calliditas Therapeutics AB (publ) to post $-1 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Calliditas Therapeutics AB (publ) Price Performance

Shares of Calliditas Therapeutics AB (publ) stock opened at $40.00 on Friday. Calliditas Therapeutics AB has a 12-month low of $15.25 and a 12-month high of $43.00. The firm has a market capitalization of $1.19 billion, a PE ratio of -21.62 and a beta of 1.77. The company has a quick ratio of 2.59, a current ratio of 2.69 and a debt-to-equity ratio of 9.44. The stock’s fifty day moving average is $40.06 and its 200-day moving average is $36.13.

Calliditas Therapeutics AB (publ) Company Profile

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.